epiK™ incorporates a Saturation Discovery approach to target screening, triangulate disease relevant biology, and allow Kalypsys to make the best selections for preferred chemical matter. Larger View
Kalypsys proprietary ultra high throughput screening and profiling automation enables the characterization of discrete molecular targets and entire cellular pathways at an unprecedented speed and scale. These technologies are integral to Saturation Discovery – the intensive, systematic examination of disease pathways or mechanisms.
Saturation Discovery begins with multiple parallel ultra high throughput screening campaigns against multiple molecular targets potentially relevant to a disease process. These targets are interrogated using the Kalypsys chemical library, a well characterized, structurally diverse collection of one million drug lead-like compounds.
Multi-dimensional potency, selectivity, and efficacy data are computationally extracted using proprietary informatics software to facilitate rapid hit selection and subsequent chemical optimization. The resulting drug leads are evaluated via streamlined disease-relevant pharmacological testing funnels to quickly identify the target(s) and lead compound(s) with the greatest efficacy potential and the most attractive side effect profile.
Ultimately, Saturation Discovery creates detailed, quality data packages that support the early selection of the discovery programs with the highest probability of clinical success. Back to top